CO4750811A1 - Acidos 3-sustituidos-2-aminobiciclo [3.1.0] hexano-2,6- dicarboxilicos - Google Patents

Acidos 3-sustituidos-2-aminobiciclo [3.1.0] hexano-2,6- dicarboxilicos

Info

Publication number
CO4750811A1
CO4750811A1 CO96059737A CO96059737A CO4750811A1 CO 4750811 A1 CO4750811 A1 CO 4750811A1 CO 96059737 A CO96059737 A CO 96059737A CO 96059737 A CO96059737 A CO 96059737A CO 4750811 A1 CO4750811 A1 CO 4750811A1
Authority
CO
Colombia
Prior art keywords
group
aromatic
monocyclic
optionally substituted
heteroaromatic
Prior art date
Application number
CO96059737A
Other languages
English (en)
Inventor
Fernandez Carmen Dominguez
Helton David Reed
Steve Marc Massey
James Allen Monn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605430.9A external-priority patent/GB9605430D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4750811A1 publication Critical patent/CO4750811A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula:en la que X representa un enlace, S, O u NRa ; R representa un grupo alquilo C1 -C6 , un grupo alquenilo C2 -C6 ; un grupo alquinilo C2 -C6 ; un grupo aromático opcionalmente sustituido; un grupo heteroaromático opcionalmente sustituido; un grupo carbocíclico no aromático; un grupo heterocíclico no aromático; un grupo carbocíclico monocíclico no aromático condensado con uno o dos grupos aromáticos o heteroaromáticos monocíclicos; un grupo heterocíclico monocíclico no aromático condensado con uno o dos grupos aromáticos o heteroaromáticos monocíclicos; o un grupo alquilo C1 -C6 , alquenilo C2 -C6 o alquinilo C2 -C6 que está sustituido con uno, dos o tres grupos seleccionados de forma independiente entre un grupo aromático opcionalmente sustituido, un grupo heteroaromático opcionalmente sustituido, un grupo carbocíclico no aromático, un grupo heterocíclico no aromático, un grupo carbocíclico monocíclico no aromático condensado con uno o dos grupos aromáticos o heteroaromáticos monocíclicos y un grupo heterocíclico monocíclico no aromático condensado con uno o dos grupos aromáticos o heteroaromáticos monocíclicos; Ra , representa hidrógeno o un grupo de fórmula (CO)n Rb ; n es 0 ó 1; y Rb es como se ha descrito para R; o uno de sus ésteres o amidas metabólicamente lábiles no tóxicos; o una de sus sales farmacéuticamente aceptables.
CO96059737A 1995-11-16 1996-11-13 Acidos 3-sustituidos-2-aminobiciclo [3.1.0] hexano-2,6- dicarboxilicos CO4750811A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US687195P 1995-11-16 1995-11-16
GBGB9605430.9A GB9605430D0 (en) 1996-03-15 1996-03-15 Excitatory amino acid receptor antagonists

Publications (1)

Publication Number Publication Date
CO4750811A1 true CO4750811A1 (es) 1999-03-31

Family

ID=26308934

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96059737A CO4750811A1 (es) 1995-11-16 1996-11-13 Acidos 3-sustituidos-2-aminobiciclo [3.1.0] hexano-2,6- dicarboxilicos

Country Status (13)

Country Link
EP (1) EP0774455A1 (es)
JP (1) JP2000500752A (es)
KR (1) KR19990067597A (es)
CN (1) CN1202103A (es)
AR (2) AR004600A1 (es)
AU (1) AU703093B2 (es)
BR (1) BR9611521A (es)
CA (1) CA2237598A1 (es)
CO (1) CO4750811A1 (es)
EA (1) EA000894B1 (es)
TW (1) TW427973B (es)
WO (1) WO1997017950A1 (es)
YU (1) YU60896A (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000015A1 (en) * 1997-07-18 2000-05-17 Georgetown University Bicyclic metabotropic glutamate receptor ligands
US6825211B1 (en) 1997-07-18 2004-11-30 Georgetown University Bicyclic metabotropic glutamate receptor ligands
EP1396273A1 (en) * 1998-03-17 2004-03-10 Pfizer Products Inc. Bicyclo(2.2.1.)heptanes and related compounds
KR100372981B1 (ko) * 1998-03-17 2003-02-25 화이자 프로덕츠 인크. 비시클로[2.2.1]헵탄 및 관련 화합물
DK1110943T3 (da) 1998-08-31 2004-10-11 Taisho Pharmaceutical Co Ltd 6-fluorbicyclo[3.1.0]hexanderivater
CH694053A5 (de) * 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
WO2003061698A1 (fr) 2001-12-27 2003-07-31 Taisho Pharmaceutical Co.,Ltd. Derives de 6-fluorobicyclo[3.1.0]hexane
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
TWI520935B (zh) 2010-11-18 2016-02-11 美國禮來大藥廠 作為ｍＧｌｕＲ２／３拮抗劑之４－經取代－３－苯基磺醯基甲基－雙環［３.１.０］己烷化合物
ES2682959T3 (es) * 2010-11-18 2018-09-24 Eli Lilly And Company Compuestos de 3-benciloxi-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mGLuR 2/3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981880A (en) * 1969-03-14 1976-09-21 The Upjohn Company Racemic prostaglandins of the 2-series and analogs thereof
CA1278577C (en) * 1985-11-18 1991-01-02 Tatsuo Tsuri Bicyclic sulfonamide derivatives
WO1996004900A1 (en) * 1994-08-12 1996-02-22 Eli Lilly And Company Composition and method for protection against drug dependency
PL182285B1 (pl) 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
ES2162936T3 (es) * 1994-08-12 2002-01-16 Lilly Co Eli Tratamiento de la ansiedad.

Also Published As

Publication number Publication date
AU703093B2 (en) 1999-03-18
AR004601A1 (es) 1998-12-16
AU7731096A (en) 1997-06-05
AR004600A1 (es) 1998-12-16
KR19990067597A (ko) 1999-08-25
JP2000500752A (ja) 2000-01-25
EP0774455A1 (en) 1997-05-21
YU60896A (sh) 1998-12-23
WO1997017950A1 (en) 1997-05-22
TW427973B (en) 2001-04-01
CA2237598A1 (en) 1997-05-22
BR9611521A (pt) 1999-06-29
CN1202103A (zh) 1998-12-16
EA199800380A1 (ru) 1998-10-29
EA000894B1 (ru) 2000-06-26

Similar Documents

Publication Publication Date Title
CO4770955A1 (es) Acidos 4-amino-2-heterobiciclo [3.1.0] hexano -4,6- dicarboxilicos
NO953837D0 (no) Heterocykliske derivater som inhibitorer for blodplateaggregering
BR0010555A (pt) Inibidores de neuraminidases
UY27357A1 (es) Nuevos agentes antidiabéticos .
BR9714310A (pt) Composição farmacêutica
DK0650960T3 (da) Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
DK0560268T3 (da) Substituerede pipecolinsyrederivater som HIV-proteasehæmmere
LU91403I2 (fr) Formulation couverte par les revendications 1,2,5,6,7,8,9,11 et 13 comprenant tout ester et sels pharmaceutiquement acceptables des composés individuels Nom du produit: Aerinaze (Desloratadine/Pseudoephedrine)
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
NO944162L (no) Substituerte heterosykliske karboksylsyreamider, deres fremstilling og deres anvendelse som legemiddel
CO4750811A1 (es) Acidos 3-sustituidos-2-aminobiciclo [3.1.0] hexano-2,6- dicarboxilicos
EA199900332A1 (ru) β-СУЛЬФОНИЛ ГИДРОКСАМОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИЧНЫХ МЕТАЛЛОПРОТЕИНАЗ
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
HUP0100812A3 (en) Alpha-hydroxy, -amino and -fluoro derivatives of betha-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors
NO991994L (no) Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriksmetalloproteaseinhibitorer
UY24425A1 (es) Derivados de tiol con actividad inhibidora de metalopeptidasa.
UY24697A1 (es) Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa
AR025351A1 (es) Agonistas retinoides selectivos par
ES2182090T3 (es) Nuevos derivados de pirrol.
ES2165193T3 (es) Metodo para aumentar la actividad de una enzima.
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
DE69828522D1 (de) Antithrombotische mittel
CO4750819A1 (es) Procedimientos para inhibir el inhibidor del activador del plasminogeno 1
ECSP961931A (es) Antagonistas de receptor de aminoacidos excitadores